Skip to main content
Cabaletta Bio, Inc. logo

Cabaletta Bio, Inc. — Investor Relations & Filings

Ticker · CABA ISIN · US12674W1099 US Professional, scientific and technical activities
Open in API
Filings indexed 415 across all filing types
Latest filing 2026-06-11 Declaration of Voting R…
Country US United States of America
Listing US CABA

About Cabaletta Bio, Inc.

https://www.cabalettabio.com/

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company utilizes its Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) platform to develop treatments that aim to provide deep, durable, and potentially curative responses. Its lead product candidate, rese-cel, is a fully human CD19-CAR T cell therapy designed to transiently eliminate B cells, thereby enabling an "immune system reset." Rese-cel is being advanced in Phase 1/2 clinical trials for a range of autoimmune diseases, including systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 6% confidence The document is a U.S. SEC Form 8-K “Current Report” reporting the results of the Annual Meeting of Stockholders, including detailed vote tallies for director elections, ratification of auditors, charter amendment, executive compensation, and adjournment proposal. This is precisely a Declaration of Voting Results & Voting Rights Announcement, matching category DVA.
2026-06-11 English
8-K
Regulatory Filings Classification · 92% confidence The document is a Form 8-K “Current Report” filed with the SEC under the Securities Exchange Act of 1934, reporting Regulation FD disclosure (Item 7.01) and other events (Item 8.01) and furnishing a press release and corporate presentation. It does not contain full financial statements or earnings highlights, nor is it a solicitation, governance proxy, or other specialized form. As a general SEC current report, it is best classified under Regulatory Filings (RNS).
2026-06-03 English
DEFA14A
Proxy Solicitation & Information Statement
2026-06-01 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K
Earnings Release Classification · 89% confidence The document is a Form 8-K with Item 2.02 ‘Results of Operations and Financial Condition’ announcing Q1 financial results via a press release furnished as Exhibit 99.1. This corresponds to an Earnings Release (initial announcement of quarterly results), not the full quarterly report or just a publication notice. Therefore, it should be classified as ER. Q1 2026
2026-05-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a United States SEC Form 8-K, a current report filed under the Securities Exchange Act of 1934. It furnishes a press release and a corporate presentation as exhibits under Items 7.01 and 8.01, making this a regulatory announcement rather than a full financial report or earnings release. This places it squarely in the general “Regulatory Filings” category.
2026-05-14 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.